Podcasts about ctcl

Imagine a group of colleges the provide a high impact educational experience where students are placed at the center not only during their four years, but also during the admissions process. Imagine a group of colleges that are accessible, affordable and where you don't have to be a finished product before you enroll. Well, folks, that's the Colleges That Change Lives group. Join Joel and Chris as they talk to Ann Marano, executive director of CTCL, and Emily Roper-Doten, VP for Undergrad Admission and Financial Assistance and Chief Enrollment Officer at Clark University, about colleges that truly do change lives. Music on this episode comes from the Free Music Archive by Lite Saturation and Jahzzar. https://freemusicarchive.org/music/lite-saturation/sport-rock-trailer/sport-rock-trailer/ https://freemusicarchive.org/music/lite-saturation/sport-rock-trailer/sport-rock-trailer-short/ https://freemusicarchive.org/music/Jahzzar/Message/A_Message_1541/

A Cutaneous T-cell Lymphoma (CTCL) diagnosis can raise many questions, from understanding symptoms to exploring treatment options.  In this episode,… The post Cutaneous T-Cell Lymphoma (CTCL): From Diagnosis to Innovation first appeared on The Bloodline with LLS.

What do Guilford College and Noble Academy have in common? Hear from Guildford's Associate Vice President for Enrollment and Retention talk about a school that, like Noble, offers small class sizes, values student diversity, and provides academic resources to students who learn differently. It's exciting to imagine the potential for future collaboration!Produced in 2024 by Gayle Kolodny Cole and Efren Renteria for Noble Academy, a school for students with learning differences in Greensboro, NC.  https://www.nobleknights.org/

Proactive's Tylah Tully breaks down ‘Just the Facts' of the latest news from Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF). The company has received US FDA clearance to proceed with Phase 2 clinical trials for its Ras pathway inhibitor, PTX-100. This study will focus on relapsed and refractory cutaneous T-cell lymphomas (r/r CTCL). The decision follows the completion of a Phase 1b trial involving 19 T-cell lymphoma patients, which demonstrated an excellent safety profile and a 42% overall response rate. Among evaluable r/r CTCL patients, five of seven experienced clinical benefits. The global Phase 2 trial will enrol 115 patients across 15 sites in Australia, the US and Europe. It will consist of two parts: dose optimisation and efficacy assessments. Primary endpoints include objective response rate, with secondary metrics focusing on progression-free survival, overall survival, safety, and quality of life. The company describes FDA clearance as a transformative milestone, reflecting years of preclinical and clinical development. Prescient aims to collaborate with global CTCL experts to deliver a safe and effective therapy for this area of unmet need. The announcement drove a 55% surge in the company's shares. #ProactiveInvestors #PrescientTherapeutics #ASX #OTC #PTX100 #FDAApproval #ClinicalTrials #OncologyResearch #TCellLymphoma #CTCL #CancerTreatment #OrphanDrug #Phase2Trial #GlobalTrial #DrugDevelopment #MedicalInnovation #PatientCare #RasPathway #CutaneousLymphoma #BiotechNews #ClinicalResearch #ASXStocks #PharmaInnovation

In this episode of Cutaneous Miscellaneous, host Nicholas Brownstone, MD, welcomes guest Stephanie Fabbro, MD, to explore the evolving role of artificial intelligence (AI) in dermatology, with practical applications for residents and early-career dermatologists. They begin with a board review on cutaneous T-cell lymphoma (CTCL) and its most common form, mycosis fungoides (MF), highlighting key diagnostic features, histological findings, and hypopigmented variants in skin of color. They explore treatment options and clinical pearls for CTCL variants like Sézary syndrome and lymphomatoid papulosis. The discussion then transitions to AI's potential to enhance the residency experience. Dr Fabbro shares insights on using AI for clinical differentials, board prep, and residency candidate selection. She offers practical tips on leveraging AI for time management, staying current with dermatologic research, and simplifying tasks like clinic notes and contract reviews. Tune in to learn how AI can transform your residency experience and support your journey into dermatologic practice!

Welcome to this month's P4A Let's Talk Rare podcast episode by Partners4Acess. Today, Georgie and Owen are joined by Leonard Mazur, CEO of Citius Pharmaceuticals, to discuss their innovative therapy, Lymphir, for cutaneous T-cell lymphoma (CTCL). Leonard shares his journey with Citius, from its founding in 2013 to the recent resubmission of Lymphirto the FDA, and discusses the drug's potential to alleviate severe itching for the 21,000 annual CTCL patients in the U.S. The conversation also covers Citius's commercialisation plans and ongoing trials exploring Lymphir's use for other conditions. Join Georgie, Leonard, and co-host Owen for an insightful discussion on how Citius is committed to improving patient quality of life through groundbreaking treatments! Leonard explains how Citius acquired Lymphir in 2021, a drug facing regulatory challenges that they've addressed for FDA resubmission, with potential approval expected. They discuss Lymphir's benefits, especially for CTCL patients, including its potential to relieve severe itching and outline the company's commercialisation plans with Eversana. Leonard emphasises the team's extensive expertise as vital to navigating the regulatory process. They also explore Lymphir's off-label potential for other cancers, with ongoing trials at major universities. The conversation closes on the rewarding impact of pharmaceutical work on patient lives, underscoring Citius's commitment to addressing unmet medical needs through innovative treatments. Leonard Mazur Bio: Leonard Mazur is a seasoned entrepreneur and executive with over five decades of experience in the pharmaceutical industry. He is known for his skill in founding and growing multiple healthcare companies. Currently CEO of Citius Pharmaceuticals, Leonard previously co-founded Leonard-Meron Biosciences and Akrimax Pharmaceuticals. He also led Triax Pharmaceuticals as COO, specialising in dermatology, and successfully sold his dermatological company, Genesis Pharmaceuticals, to Pierre Fabre in 2003. His extensive background spans roles in sales, marketing, and business development at Medicis, ICN, Knoll Pharma, and Cooper Labs. Born in Germany, Mazur holds an MBA from Temple University, where he also earned his undergraduate degree. He is an Ellis Island Medal of Honor recipient. Episode Resources: Leonard Mazur on LinkedIn Citius Pharmaceuticals Website Owen Bryant on LinkedIn Georgina Rack on LinkedIn Partners4Access Website  P4A Let's Talk Rare podcast on Apple Podcasts

In today's episode, supported by Citius Pharmaceuticals, we had the pleasure of speaking with Francine Foss, MD, to discuss the FDA approval of denileukin diftitox-cxdl (Lymphir) for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma (CTCL) who have received 1 or more prior systemic therapies. Dr Foss is a professor of medicine (hematology) and dermatology and the director of the Multidisciplinary T Cell Lymphoma Program at the Yale School of Medicine, as well as the scientific leader of Lymphoma CRT at Yale Cancer Center in New Haven, Connecticut.  On August 8, 2024, the FDA approved denileukin diftitox for the treatment of patients with relapsed/refractory CTCL who have received at least 1 prior systemic therapy. This regulatory decision was supported by findings from the phase 3 Study 302 (NCT01871727), in which patients who received the agent (n = 69) achieved an objective response rate of 36.2% (95% CI, 25.0%-48.7%) per independent review committee assessment, including a complete response rate of 8.7%. In our exclusive interview, Dr Foss discussed the significance of this approval, key efficacy and safety data from Study 302, and her excitement about reintroducing an agent to the CTCL treatment paradigm that can induce particularly robust responses.

Yuliya Linhares, MD is a medical oncologist specializing in the comprehensive treatment of lymphoma and serves as chief of Lymphoma Services at Miami Cancer Institute. In this video, Dr. Linhares provides an overview of cutaneous T-cell lymphoma (CTCL) and discusses some strategies for shortening the diagnostic journey of this rare cancer.The diagnosis of CTCL is often challenging; as a result, delays in diagnosis (and subsequent work-up and treatment) can be significant. Part of the reason is the variability in how individual patients present with CTCL and its subtypes. Because mycosis fungoides progresses slowly, some patients may not experience progression beyond their initial symptoms, even beyond 10 years. Patients with mycosis fungoides or Sézary syndrome also have overlap in manifestations; in fact, Sézary syndrome was once classified as a malignant, leukemic variant of mycosis fungoides but is now recognized as a distinct CTCL subtype.Patients with mycosis fungoides may progress through three phases of skin symptoms. The first may feature little more than transient red, scaly areas of skin on the buttocks and torso. The plaques may be hyper- or hypopigmented. As such, these symptoms can be easily misidentified as common skin conditions such as eczema or psoriasis. The variability of signs and symptoms also adds to the challenge of making a timely, clear-cut diagnosis.In the second phase, patients with progressing disease may develop palpable, scaly, reddish-brown plaques that appear on any portion of the body. Over time, the affected areas of skin may grow, merging with other affected regions. Patients' skin presentation during this stage can vary considerably: Some patients may experience severe pruritus or pain in these scaly bumps, which can result in sleep disturbances and other challenges to quality of life. Other patients may remain asymptomatic other than the skin's appearance.Disease presentation is a bit more consistent in patients who have progressed to the third phase of skin symptoms. Some patients may develop mushroom-shaped skin tumors that can cause skin ulceration and infection. Even for patients with mycosis fungoides reaching this phase of skin progression, malignant spread is uncommon (only 10% will experience metastases to major organs).While patients with Stage III mycosis fungoides experience widespread erythema (over 80% of body surface area), erythroderma is a consistent feature of Sézary syndrome. This rash will often be associated with severe pruritus and peeling.In addition to erythroderma and B2 blood involvement, patients with Sézary syndrome will typically have several other characteristic signs: generalized lymphadenopathy, opportunistic infections, and alopecia. The liver and possibly the spleen will be enlarged, and patients often have very thick, coarse skin on the soles of the feet and palms of the hands (i.e., palmoplantar keratoderma).Diagnosis is usually made with a patient history, complete physical exam, blood tests, biopsy of skin lesions, computed tomography imaging, and sometimes lymph node biopsy and/or bone marrow biopsy. These methods can also be useful in determining the stage of disease, especially whether the lymph nodes have been involved and whether the cancerous cells have spread to blood and other organs. In addition to eczema and psoriasis, the differential diagnosis may include nonspecific dermatitis, lichen, lupus, pseudolymphoma, parapsoriasis, and toxidermia.To learn more about CTCL, visit our Cutaneous T-Cell Lymphoma (CTCL) Learning Center page. https://checkrare.com/cutaneous-t-cell-lymphoma-2/

Larisa Geskin, MD, Professor of Dermatology at Columbia University Medical Center and Director of the Comprehensive Skin Cancer Center at the Division of Cutaneous Oncology in the Department of Dermatology, discusses the challenges of diagnosing cutaneous T-cell lymphoma (CTCL).The diagnosis of CTCL is often challenging; as a result, delays in diagnosis (and subsequently work-up and treatment) can be significant. Part of the reason is the variability in how individual patients present with CTCL and its subtypes. Because mycosis fungoides progresses slowly, some patients may not experience progression beyond their initial symptoms, even beyond 10 years. Patients with mycosis fungoides or Sézary syndrome also have overlap in manifestations; in fact, Sézary syndrome was once classified as a malignant, leukemic variant of mycosis fungoides but is now recognized as a distinct CTCL subtype.Patients with mycosis fungoides may progress through three phases of skin symptoms. The first may feature little more than transient red, scaly areas of skin on the buttocks and torso. The plaques may be hyper- or hypopigmented. As such, these symptoms can be easily misidentified as common skin conditions such as eczema or psoriasis. The variability of signs and symptoms also adds to the challenge of making a timely, clear-cut diagnosis.In the second phase, patients with progressing disease may develop palpable, scaly, reddish-brown plaques that appear on any portion of the body. Over time, the affected areas of skin may grow, merging with other affected regions. Patients' skin presentation during this stage can vary considerably: Some patients may experience severe pruritus or pain in these scaly bumps, which can result in sleep disturbances and other challenges to quality of life. Other patients may remain asymptomatic other than the skin's appearance.Disease presentation is a bit more consistent in patients who have progressed to the third phase of skin symptoms. Some patients may develop mushroom-shaped skin tumors that can cause skin ulceration and infection. Even for patients with mycosis fungoides reaching this phase of skin progression, malignant spread is uncommon (only 10% will experience metastases to major organs).While patients with Stage III mycosis fungoides experience widespread erythema (over 80% of body surface area), erythroderma is a consistent feature of Sézary syndrome. This rash will often be associated with severe pruritus and peeling.In addition to erythroderma and B2 blood involvement, patients with Sézary syndrome will typically have several other characteristic signs: generalized lymphadenopathy, opportunistic infections, and alopecia. The liver and possibly the spleen will be enlarged, and patients often have very thick, coarse skin on the soles of the feet and palms of the hands (i.e., palmoplantar keratoderma).Diagnosis is usually made with a patient history, complete physical exam, blood tests, biopsy of skin lesions, computed tomography imaging, and sometimes lymph node biopsy and/or bone marrow biopsy. These methods can also be useful in determining the stage of disease, especially whether the lymph nodes have been involved and whether the cancerous cells have spread to blood and other organs. In addition to eczema and psoriasis, the differential diagnosis may include nonspecific dermatitis, lichen, lupus, pseudolymphoma, parapsoriasis, and toxidermia.To learn more about CTCL, visit our Cutaneous T-Cell Lymphoma (CTCL) Learning Center page. https://checkrare.com/ctcl-the-role-of-dermatologists-in-diagnosing-and-caring-for-patients/

Soligenix CEO Chrisopher Schaber joined Steve Darling from Proactive to announce an interim update on the open-label, investigator-initiated study evaluating extended HyBryte™ treatment for up to 12 months in patients with early-stage cutaneous T-cell lymphoma. To date, six patients have been enrolled and treated with HyBryte™ over a time period ranging up to 44 weeks. Patients have responded positively to HyBryte™ therapy with 75% (3 of the 4 subjects who have completed at least 12 weeks of therapy) already achieving "Treatment Success," as predefined in the study's protocol as ≥50% improvement in their cumulative mCAILS score compared to Baseline. Schaber also told Proactive that of the three Treatment Successes, two were achieved within the first 12 weeks of treatment and the third within 18 weeks. Of the remaining three patients, two have only recently started HyBryte™ therapy and have not yet reached their first efficacy evaluation visit, and the other had a substantial improvement documented at the Week 18 visit but has not yet achieved the success threshold. Patients have the potential to be treated for up to 12 months with twice-a-week dosing (visible light activation following ointment application by 24 ± 6 hours). The study also allows for potential transition to a "real-world" setting with home-use. Another vertical from the company is for public health solutions, which include heat-stable vaccines for emerging infectious diseases and biodefense. The latter segment has received over $60 million in non-dilutive funding from the US government.Soligenix's vaccines are notable for their heat stability, allowing them to be stored outside refrigerators for over two years at temperatures exceeding 100°F. This makes them particularly valuable in regions like Sudan, where cold chain distribution is challenging. #proactiveinvestors #soligenixinc #nasdaq #sngx #Biopharmaceutical, #RareDiseases, #Oncology, #Inflammation, #PublicHealth, #HeatStableVaccines, #Ebola, #Marburg, #Biodefense, #NonDilutiveFunding, #HyBryte, #CTCL, #Psoriasis, #ClinicalTrials, #USGovernmentFunding, #TopicalTherapy, #VisibleLightTherapy, #Biotech, #MedicalResearch#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Dupi and CTCL... It's complicated - Dupi and lymphoid reactions - Dupi worsens CTCL - Updates in CSU pathophys and treatment - Calcinosis cutis options - Petroleum jelly: It's awesome, and here's why - Want to donate to the cause? Do so here! Donate to the podcast: uofuhealth.org/dermasphere Check out our video content on YouTube: https://www.youtube.com/@dermaspherepodcast and VuMedi!: https://www.vumedi.com/channel/dermasphere/ The University of Utah's Dermatology ECHO: ⁠https://physicians.utah.edu/echo/dermatology-primarycare - ⁠ Connect with us! - Web: ⁠https://dermaspherepodcast.com/⁠ - Twitter: @DermaspherePC - Instagram: dermaspherepodcast - Facebook: https://www.facebook.com/DermaspherePodcast/ - Check out Luke and Michelle's other podcast, SkinCast! ⁠https://healthcare.utah.edu/dermatology/skincast/⁠ Luke and Michelle report no significant conflicts of interest… BUT check out our friends at: - ⁠Kikoxp.com ⁠(a social platform for doctors to share knowledge) - ⁠https://www.levelex.com/games/top-derm⁠ (A free dermatology game to learn more dermatology!)

Welcome to a new episode of the Evidence-Based Hair Podcast, where we discuss some questions surrounding the relationship between dupilumab and lymphoma. This episode dives deep into a study by Hasan and colleagues that explores the fascinating and somewhat controversial relationship between Dupilumab, a drug often used to treat atopic dermatitis patients with alopecia areata, and an increased risk of Cutaneous T-Cell Lymphoma (CTCL). Despite its potential benefits, does Dupilumab truly cause CTCL, or does it simply unmask the disease in patients who were previously misdiagnosed? Using information from a vast database, authors examined whether patients using dupilumab showed an increased incidence of CTCL compared to those who did not. Findings suggest that users of the drug have a four-fold increased risk of CTCL.   While uncertainties remain on whether Dupilumab triggers lymphomas, causes benign lymphoid reactions, or accelerates existing CTCL, this episode underscores the drug's potential risks and the importance of careful diagnostics before prescribing it. As we continue to gather data and debate the varying viewpoints, we invite you to join us in disentangling the complex relationship between Dupilumab and CTCL.  Stay tuned for our next episode, where we explore drug-induced alopecia areata and the potential triggering effects of new monoclonal antibodies.     donovanmedical  Edited• Season 7 of the Evidence Based Hair Podcast has started. This week I review several fascinating studies: The podcast can be accessed wherever you listen to your podcasts or via the DonovanMedical youtube channel. REFERENCES IN THIS EPISODE   Hasan I et al. Dupilumab therapy for atopic dermatitis is associated with increased risk of cutaneous T cell lymphoma: a retrospective cohort study. J Am Acad Dermatol. 2024 Apr 6:S0190-9622(24)00566-8. doi: 10.1016/j.jaad.2024.03.039. Online ahead of print. Jfri A et al. Diagnosis of mycosis fungoides or Sézary syndrome after dupilumab use: A systematic review. J Am Acad Dermatol . 2023 May;88(5):1164-1166. doi: 10.1016/j.jaad.2022.12.001. Epub 2022 Dec 5. Espinosa ML et al. Progression of cutaneous T-cell lymphoma after dupilumab: Case review of 7 patients. J Am Acad Dermatol . 2020 Jul;83(1):197-199. doi: 10.1016/j.jaad.2020.03.050. Epub 2020 Mar 27.

On today's episode, Ethan is joined by Christine Bowman, Assistant VP for Admission at Southwestern University. In part 6 in our series on What Colleges Want, Ethan and Christine get into: What is demonstrated interest and how do colleges track it?  How important is demonstrated interest to a student's chance of getting in? How might students find out if a particular school considers demonstrated interest in their admission review? What are some practical ways you can demonstrate your interest to colleges? Christine Bowman is the Assistant VP for Admission at Southwestern, where she oversees the admission department to set enrollment and retention philosophies. She has a Masters in Higher Ed Administration from UT-Austin, was the Co-Chair for the 2007 NACAC National Conference in and has served two terms as the Chair of the Colleges that Change Lives Board of Directors (see last season's episode with Ann Marano for more on CTCL's work). She currently serves on the advisory board of ROCA-NM (Rural Opportunities for College Access) and, with almost 30 years of experience in the admission profession, Christine believes in guiding students to find the right college fit and regularly gives presentations encouraging a stress-free college search process. We hope you enjoy the conversation!    Play-by-Play 2:15 - What is demonstrated interest? 5:00 - Why might demonstrated interest be important to colleges? 8:22 - What is yield? 11:24 - How can students demonstrate interest for a particular school?  15:17 - What can colleges track? 18:52 - For whom does demonstrated interest matter most?  23:47 - How to “break up” with a college 27:05 - What are some practical tips for students as they reach out to a college? 30:10 - How might an admissions officer use demonstrated interest? 32:58 - What ways can students demonstrate interest without visiting campus? 37:24 - What is the difference between early action, early decision, and regular decision? 40:25 - How important is the college interview? 48:10 - What can parents do to support their students during this process? 53:02 - Closing advice for parents, students, and counselors    Resources A Behind the Scenes Look at Demonstrated Interest w/Christine Bowman (Southwestern University) What is Demonstrated Interest? A Practical How-To Guide Factors in the Admission Decision (NACAC Report) How to Decide Whether to Apply Early Action (EA) or Early Decision (ED) College Interview Tips and Strategies - The Ultimate Guide CEG Podcast Episode 411: Finding Your Why, What a Liberal Arts Education Really Is, and How to Figure out What You Actually Want w/ Ann Marano (CTCL)  

* Unveiling the Enigma: US DoD's Mysterious COVID-19 Research Contract in Ukraine – A Timeline That Defies the Pandemic Narrative!". * Our government lied to you about Covid-19!!!! They knew prior to any information being released to the public. This will explain the war in Ukraine once and for all. * In early January 2020, reports surfaced regarding a novel coronavirus, initially presenting as a pneumonia-like illness in Wuhan, China. However, the official designation of Covid-19 by the WHO did not occur until February 11, 2020. Curiously, US DOD, data indicates a contract awarded on November 12, 2019, to Labyrinth Global Health INC. for 'COVID-19 Research.' This timing predates both the alleged emergence of the novel coronavirus and the official designation of Covid-19 by one and three months, respectively. * d official naming of Covid-19. Adding to the intrigue, the location specified for the Covid-19 research contract is Ukraine, a country entangled in geopolitical tensions where the US Military Industrial Complex is reportedly engaged in a proxy war against Russia. * CIA and foreign intelligence agencies illegally targeted 26 Trump associates before 2016 Russia collusion claims. Former CIA Director John Brennan identified and presented the targets to the US's intelligence-sharing partners in the so-called “Five Eyes” agencies – the intelligence-gathering organizations in the US, United Kingdom, Canada, Australia and New Zealand – according to a report published Monday on Michael Shellenberger's Public Substack. * Former FBI lawyer Kevin Clinesmith was sentenced to probation in 2021 after admitting that he falsified an e-mail to renew a wiretap against former Trump campaign adviser Carter Page. * Last March, Special Counsel John Durham concluded that the FBI investigation of Trump's alleged collusion with Russia was “seriously flawed” and had no basis in evidence, after a four-year review of the probe. * We are releasing information on a secret 2020 Election Day phone call organized by The Cybersecurity and Infrastructure Security Agency (CISA). * FOIA Documents Reveal Secret 2020 Election Day Meeting With CISA, Dominion, ES&S, ERIC, FBI, Leftist Organizations, State Officials, and Others. * We have evidence that a private meeting was organized by CISA officials on November 3, 2020, at 3:30 PM Eastern Time with select members of a secret “Election Security Initiative.” * The report revealed collusion between the US government (the FBI, DOJ, EAC, and CISA), with progressive groups and individuals fueled by progressive money related to US elections (like the Elections Group, CTCL, and Brennan Center), along with individuals from US corporations like Microsoft.

Today we have Heather Murphy, the Development Director of Couple to Couple League. She shares with us a new initiative that CTCL has for women during Lent. We were blown away, by what she shared. This program would be fantastic for all teens and young adult women. It could also be helpful for any woman who is struggling month to month with her cycle.  Couple to Couple League, the premier provider of Natural Family Planning resources just launched Revelation90, a 90 day course where women take a deep dive into their wellness habits to reveal their healthiest, happiest selves. Drawing on the expertise of program partners SoulCore and Temple+Table, Revelation90 provides a holistic answer to the persistent health problems that women face today. The inaugural Revelation90 challenge will kick off on Ash Wednesday, February 14, and end 90 days later on the Feast of Our Lady of Fatima, May 13. Katie Zulanas, Executive Director of Couple to Couple League, says Revelation90 is the answer to a problem that the Couple to Couple League has observed for years. “Working with hundreds of thousands of women in helping them learn about and understand their fertility, we have unfortunately seen a disturbing trend of cycles becoming more irregular,” Zulanas said. “A woman's cycle is an extremely accurate indicator of overall health. Revelation90 will not only give you great insight into your health, it will give you the tools needed to design a happier, healthier, smarter lifestyle.” To register or get more info about Revelation 90 visit www.revelation90.org Our listeners (and friends and family) can use "beloved90" to get 50% off the Revelation90 program!  Revelation 90 Info Trailer  https://www.youtube.com/watch?v=jZb6jd9ALVg Couple To Couple League ⁠https://ccli.org/⁠ --- Send in a voice message: https://podcasters.spotify.com/pod/show/hisbelovedoftexas/message Support this podcast: https://podcasters.spotify.com/pod/show/hisbelovedoftexas/support

What do you get when you get three former CTCL admissions counselors together discussing a magical candy committee? An extended J Term episode, that's what. We are thrilled to bring you the extended cut of our interview from last summer with Sawyer Earwood, Independent Educational Consultant and owner of Virtual College Consulting in Every Town, USA. More important topics than the candy committee: the value of phone calls, the impact of a counselor, and the power of relational recruiting. --- Send in a voice message: https://podcasters.spotify.com/pod/show/adlunchcast/message

On Season 1 of the podcast, Ethan had a great conversation with Maria Furtado, then Executive Director of the Colleges That Change Lives organization (also known as “CTCL”). It's a lovely chat and to date one of our most downloaded episodes.  On today's episode Ethan had the pleasure of sitting down with her successor, Ann Marano, and they get into:    Where to start when it comes to the college search How to myth bust yourself (a practical exercise) What questions to ask when you're searching for a college Some things Ann and Ann and Ethan wished they had done differently when they went through the process themselves  Busting some affordability myths What it means to keep a student at the center of the college search  If you've never met Ann, you should know that she is a proud first-generation college graduate of Mount St. Mary's University (CA) who earned her M.A. in Education-Psychology from Pepperdine. She's served on several counselor advisory boards, including the Common Application Board of Directors and the Johns Hopkins University Access Advisory Board. After 20 years in college admissions counseling at several different universities and high schools and 12 years as the college bound advisor at the first all girls' public school in the state of Texas, Ann Marano moved into the role of Executive Director for the Colleges That Change Lives. We hope you enjoy the conversation.   Play-by-Play 1:57 - What is CTCL and what is Ann's role as Executive Director?  3:58 - What's it like to be a student at a liberal arts college? 8:09 - What kind of student is right for a liberal arts college?  10:01 - What's a good place to start in the college search process? 14:49 - How to combat myths about colleges  19:04 - What are some questions that are important for students and families to be asking themselves as they go through this process? 25:52 - An exercise for picturing yourself on a college campus  29:45 - What would Ann and Ethan have done differently in college? 32:04 - How does a student get a sense of a school if they're not able to visit the campus? 34:15 - College affordability at private schools 39:17 - What are some tips for parents about keeping students at the center of the search? 43:56 - Another example of what it's like to be a student at a liberal arts college 48:27 - An exercise students can do to begin this process of finding a great college 52:55 - Final thoughts / wrap-up   Resources CTCL.org CTCL How To Choose A College Brochure The Values Exercise How to Choose a College: A Step-By-Step Guide  How to Research Colleges Without Visiting a Campus Paying for College in Four Steps: The Five College Types U.S. Department of Education College Affordability and Transparency Center College Cost Transparency Initiative The Common Data Set: What It Is and How to Use It in College Admissions   

Today we are doing a deep dive into Cutaneous T Cell Lymphoma (CTCL). This uncommon yet impactful skin condition takes center stage as we seek to unravel its complexities. To have this discussion, we are fortunate to have Dr. Michael Girardi, a distinguished dermatologist and a leading authority in the field of CTCL research from Yale University. Together, we'll navigate the intricacies of CTCL, exploring its nuances, diagnosis procedures, available treatment modalities, and the promising advancements that hold the potential to transform the landscape of CTCL management. Dr. Girardi's wealth of knowledge and expertise promises to shed light on this condition, offering hope and understanding to those affected by CTCL and the medical community at large. To learn more about CTCL: https://www.hannahkopelman.com/blog/cutaneous-t-cell-lymphoma/ Connect with me across Social: Twitter: https://twitter.com/drhankopelman Instagram: https://www.instagram.com/doctor.han/ TikTok: https://www.tiktok.com/@drhankopelman Blog: https://www.hannahkopelman.com/blog/ The content of this podcast is for entertainment and educational purposes only. This content is not meant to be a substitute for medical advice or treatment for any medical condition. --- Send in a voice message: https://podcasters.spotify.com/pod/show/hannah-kopelman/message

Ginette Okoye, MD, FAAD interviewed by Brad Glick, DO, MPH, FAAD

In episode 53 of Derms and Conditions, our host James Q. Del Rosso, DO, continues his conversation with Matt Zirwas, MD, a dermatologist in Columbus, Ohio, and founder of the Bexley Dermatology Research Clinic. After reviewing localized eczematous dermatitis in part 1, they switch gears to discuss adults with scattered eczematous dermatitis in part 2. Dr. Zirwas shares several pearls for differentiating among atopic dermatitis, psoriasis, photosensitive dermatitis, CTCL, and contact dermatitis, and describes a new method for diagnosing scabies. He also discusses when to perform a biopsy and management approaches when the biopsy does not provide a clear answer. Dr. Zirwas then names several topical products with low allergenicity, including everything from cleansers and moisturizers to detergents and fabric softeners, that are beneficial to patients with sensitive skin. Dr. Del Rosso asks about disease-directed therapy and systemic treatment options, prompting Dr. Zirwas to dive into his medications of choice for each phenotype and patient population. This episode is full of pearls for a variety of eczematous and inflammatory dermatoses, so tune in to learn more!  

Dr. Myron Czuczman is the Chief Medical Officer and Executive Vice President of Citius Pharmaceuticals, which is developing an advanced treatment for cutaneous T cell lymphoma, CTCL, a rare form of non-Hodgkin lymphoma. The original version of their drug ONTAK has been reformulated, and I/ONTAK is now in clinical trials to confirm efficacy in controlling severe itching and improving the quality of life for patients. Myron explains, "This is a protein, a fusion protein, of interleukin-2, the whole molecule that has been fused with diphtheria toxin. With respect to any of the cells like the cells we're talking about, CTCL, it actually binds to the IL-2 receptor, internalizes, and in that manner, kills the tumor cells." "The agent ONTAK was taken off the market, and this new version, I/ONTAK or E7777, is a reformulation. It's more purified and it's about one and a half to two times more bioactive than the original ONTAK. From the clinical trials which led to our submission of the BLA recently, we've looked at the safety and efficacy, and it's consistent with the original formulation. There are no new safety issues, and it has good activity in patients, even heavily pretreated patients." "The issue here is, unfortunately, this disease, the relapsed/refractory CTCL, is incurable. The only time one has a chance to cure it is if you get it early, if you have young patients that have what we call an HLA compatible donor. In a very small number of patients, an allogeneic stem cell transplant could be curative. But the vast majority of these patients, who are elderly, are not candidates for allogeneic transplant. So, unfortunately, these are incurable individuals with bad diseases." @CitiusPharma #Cancer #Lymphoma #RareDisease #Immunotherapy $CTXR citiuspharma.com Listen to the podcast here

Dr. Myron Czuczman is the Chief Medical Officer and Executive Vice President of Citius Pharmaceuticals, which is developing an advanced treatment for cutaneous T cell lymphoma, CTCL, a rare form of non-Hodgkin lymphoma. The original version of their drug ONTAK has been reformulated, and I/ONTAK is now in clinical trials to confirm efficacy in controlling severe itching and improving the quality of life for patients. Myron explains, "This is a protein, a fusion protein, of interleukin-2, the whole molecule that has been fused with diphtheria toxin. With respect to any of the cells like the cells we're talking about, CTCL, it actually binds to the IL-2 receptor, internalizes, and in that manner, kills the tumor cells." "The agent ONTAK was taken off the market, and this new version, I/ONTAK or E7777, is a reformulation. It's more purified and it's about one and a half to two times more bioactive than the original ONTAK. From the clinical trials which led to our submission of the BLA recently, we've looked at the safety and efficacy, and it's consistent with the original formulation. There are no new safety issues, and it has good activity in patients, even heavily pretreated patients." "The issue here is, unfortunately, this disease, the relapsed/refractory CTCL, is incurable. The only time one has a chance to cure it is if you get it early, if you have young patients that have what we call an HLA compatible donor. In a very small number of patients, an allogeneic stem cell transplant could be curative. But the vast majority of these patients, who are elderly, are not candidates for allogeneic transplant. So, unfortunately, these are incurable individuals with bad diseases." @CitiusPharma #Cancer #Lymphoma #RareDisease #Immunotherapy $CTXR citiuspharma.com Download the transcript here

Pavlos has improved T-Cell blood counts, sleep, energy levels, body fat, mental state (better outlook on life), skin condition (he has cutaneous T-cell lymphoma [CTCL] and the frequency/occurrence of skin lesions/patches were nearly zero), and physique on the carnivore diet. Timestamps: 00:00 Trailer 00:50 Introduction 06:21 Cutaneous B-cell lymphoma 09:12 Dietary changes 18:13 Going on the carnivore diet 23:04 Current diet 26:25 Mental health on the carnivore diet 29:28 Veganism in Crete 33:10 Sunbathing 34:50 Interacting with physicians 36:29 What caused Pavlos to go vegan 42:08 Cuisine in Crete 47:04 Libido 49:17 New business ventures See open positions at Revero: https://jobs.lever.co/Revero/ Join Carnivore Diet for a free 30 day trial: https://carnivore.diet/join/ Book a Carnivore Coach: https://carnivore.diet/book-a-coach/ Carnivore Shirts: https://merch.carnivore.diet Subscribe to our Newsletter: https://carnivore.diet/subscribe/ . ‪#revero #shawnbaker #Carnivorediet #MeatHeals #HealthCreation   #humanfood #AnimalBased #ZeroCarb #DietCoach  #FatAdapted #Carnivore #sugarfree  ‪

Randy opens the show with his FIRST Twitter Warning.  The innocuous Tweet promoted tonight's show by announcing Randy's tracking of CO GOP SoS nominee, Pam Anderson. Does her ongoing work with CTCL promote Republican values and transparent elections?  Randy doesn't think so. The Tweet also asked whether YOU would buy and wear a Trump Mugshot T-Shirt if Trump actually gets arrested.  Randy's answer?  Oh, yeah!  Randy dipped in and out of the Waco Trump rally.  And scary audio of Biden and John Kerry's China love, and an epic rant over the nonsense known as (man-caused) "Climate Change."See omnystudio.com/listener for privacy information.

Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2022.11.10.515982v1?rss=1 Authors: Wang, W., Zhang, X., Zhao, N., Xu, Z.-H., Jin, K., Jin, Z.-B. Abstract: Chimeric RNAs have been found in both cancer and healthy human cells. They have regulatory effects on human stem/progenitor cell differentiation, stemness maintenance and central nervous system (CNS) development. However, their physiological functions in the retinal development remain unknown. Based on the human embryonic stem cells (hESC)-derived retinal organoids (ROs) spanning from day 0 to day 120, we present the expression atlas of chimeric RNAs throughout the developing ROs. We confirmed the existence of some common chimeric RNAs and also discovered many novel chimeric RNAs during retinal development. We focused on CTNNBIP1-CLSTN1 (CTCL) whose downregulation causes precocious neuronal differentiation and a marked reduction of neural progenitors in human cerebral organoids. Our study found that CTCL also plays a key role in human retinogenesis, CTCL loss-of-function obstructed RO differentiation but prompted the retinal pigment epithelial (RPE) differentiation. Together, this work provides a landscape of chimeric RNAs and reveals evidence for their crucial roles in human retina development. Copy rights belong to original authors. Visit the link for more info Podcast created by Paper Player, LLC

Racial disparities in care and outcomes have been well documented but the problems can be particularly acute in cases of rare, genetic diseases. One example of this is the rare blood cancer cutaneous T-cell lymphoma. African Americans are twice as likely as people of European or Asian descent to develop CTCL, are typically diagnosed with more advanced disease, and have a lower survival rate from the condition. Kyowa Kirin North America, which produces the CTCL treatment Poteligeo, is working to address racial disparities to improve the diagnosis, care, and outcomes of African American patients with CTCL. We spoke to Kyowa Kirin Vice President of Public Affairs Lauren Walrath and Co-Leader of the Immune Cell Regulation and Targeting Program at the Sidney Kimmel Cancer Center at Jefferson Health Pierluigi Porcu, about CTCL, the disparities in care and outcomes for African Americans with the condition, and what they are doing to address that.

As tuitions rise faster than inflation, more and more students and their families may wonder what value college offers and which colleges offer the most opportunities to help set them up for success. Join Mark and Anna as they speak with Ann Marano, Executive Director for the Colleges That Change Lives organization, to discuss the value of liberal arts education and what truly sets colleges in that organization a part from the hundreds of other colleges and universities in the country, including a student-centered approach to education. Learn more about Colleges that Change Lives at https://ctcl.org.

Soligenix CEO Chris Schaber joined Steve Darling from Proactive to share news the company has been very busy over the last moths with some major accomplishments including an agreement from the FDA on an initial pediatric study plan for HyBryte for the treatment of CTCL. Schaber also told Proactive the company announced it had signed a worldwide exclusive license to supply its ricin antigen to SERB Pharmaceuticals, for development of a novel therapeutic treatment against ricin toxin poisoning.

Pam Anderson is, fortunately, the Republican nominee for Secretary of State of Colorado. Of the other two candidates, one was unqualified and the other was disqualified. We're going to talk with Pam about a few things including the many failures of incumbent Democrat Jena Griswold and finally putting to bed the question of Pam's association with the Mark Zuckerberg-funded Center for Technology and Civic Life (CTCL) which many Republicans see as having been an intentionally partisan (pro-Democrat) effort. Zuckerberg said he won't make private grants to support election operations anymore but that doesn't mean he won't be involved somehow...and I understand why Republicans don't trust him. Mark Zuckerberg Ends Election Grants - The New York Times (nytimes.com). That said, I think this CTCL thing is a very tiny issue and I wish my GOP/MAGA listeners would move on to what matters: beating Jena Griswold. Pam is an exceptionally experienced candidate, perhaps the most qualified non-incumbent SoS candidate in the nation. And she'll do a tremendous job when she wins. We all need to help her and stop focusing on silly distractions.

In this week's episode we review a novel strategy for overcoming resistance to CAR T cell therapy that involves the dual targeting of myeloma cells and cancer-associated fibroblasts. We'll also explore a recent report demonstrating that loss of CCR4 expression is common after treatment of CTCL with the anti-CCR4 antibody mogamulizumab. Finally, we'll review real-world data demonstrating an association between corticosteroid exposure and risk of vaso-occlusive episodes in patients with sickle cell disease, providing further evidence that steroids should be avoided in this setting.

In today's episode:Everything coming out of Uvalde is either inconsistent, incompetent, or completely incoherentThe media seems to be creating a narrative for the people they interviewThe mayor of Uvalde has been outspoken about the policy failures of the fake administration regarding illegal immigration that is destroying his cityDHS declares that ICE/CBP will not be enforcing immigration law in Uvalde due to the incident two days after Title 42 was set to expire and did notTore Maras and Political Moonshine on strange federal expenditures in Uvalde99% of illegal immigrants claiming asylum are making invalid claims, according to a study from UCLAA Yuma woman pleads guilty to election fraud charges centered around True the VoteRecords show 20,000 Maricopa County votes received after the deadline were counted in the 2020 electionThe Thomas More Society brings new cases against the "Wisconsin 5" cities over CTCL funded dropboxes.Connect with Be Reasonable: https://linktr.ee/imyourmoderatorTo support directly:imyourmoderator.substack.comko-fi.com/imyourmoderatorbtc via coinbase: 3MEh9J5sRvMfkWd4EWczrFr1iP3DBMcKk5Merch site: https://cancel-couture.myspreadshop.com/Follow the podcast info stream: t.me/imyourmoderatorOther social platforms: Truth Social, Gab, Rumble, Bitchute, Odysee, DLive or Gettr - @imyourmoderatorVisit mypillow.com and use promo code REASONABLE to support me, Mike Lindell, and his great American company!Listen at: https://shows.acast.com/bereasonable/ or on your favorite podcast app (except Spotify, I'm banned)RSS: https://feeds.acast.com/public/shows/623c9d211c3aa5001204d6ed See acast.com/privacy for privacy and opt-out information. Become a member at https://plus.acast.com/s/be-reasonable-with-your-moderator-chris-paul.

In today's episode:Everything coming out of Uvalde is either inconsistent, incompetent, or completely incoherentThe media seems to be creating a narrative for the people they interviewThe mayor of Uvalde has been outspoken about the policy failures of the fake administration regarding illegal immigration that is destroying his cityDHS declares that ICE/CBP will not be enforcing immigration law in Uvalde due to the incident two days after Title 42 was set to expire and did notTore Maras and Political Moonshine on strange federal expenditures in Uvalde99% of illegal immigrants claiming asylum are making invalid claims, according to a study from UCLAA Yuma woman pleads guilty to election fraud charges centered around True the VoteRecords show 20,000 Maricopa County votes received after the deadline were counted in the 2020 electionThe Thomas More Society brings new cases against the "Wisconsin 5" cities over CTCL funded dropboxes.Connect with Be Reasonable: https://linktr.ee/imyourmoderatorTo support directly:imyourmoderator.substack.comko-fi.com/imyourmoderatorbtc via coinbase: 3MEh9J5sRvMfkWd4EWczrFr1iP3DBMcKk5Merch site: https://cancel-couture.myspreadshop.com/Follow the podcast info stream: t.me/imyourmoderatorOther social platforms: Truth Social, Gab, Rumble, Bitchute, Odysee, DLive or Gettr - @imyourmoderatorVisit mypillow.com and use promo code REASONABLE to support me, Mike Lindell, and his great American company!Listen at: https://shows.acast.com/bereasonable/ or on your favorite podcast app (except Spotify, I'm banned)RSS: https://feeds.acast.com/public/shows/623c9d211c3aa5001204d6ed See acast.com/privacy for privacy and opt-out information. Become a member at https://plus.acast.com/s/be-reasonable-with-your-moderator-chris-paul.

Season 1: #5 - Maria Furtado: “Know” Before No. There are over 4000 colleges and universities in the US. Let me let that sink in for a moment. There are more colleges than there are shopping malls, Apple stores, amusement parks, and national parks COMBINED. I've researched and/or visited over one hundred colleges, but I could not begin to name more than maybe 300. My question this week is, “How many could you name?” My guess is that most people would name the same 50 -150. So if this is true, why do so many shake their head, “No” to a college they've never heard of? Where did we learn this? Teachers everywhere teach students that when you don't know something, if you don't have the answer, you should ask questions. You can ask the teacher, ask a parent, ask you neighbor, or phone a friend. This week our guest, Maria Furtado, the Executive Director and national spokeswoman for Colleges That Change Lives, shares her journey to college. As the first in her family to attend college, Maria applied two golden rules; 1) Follow The Leader, and 2) Know before No. Maria's story will open your mind and heart to a group of 44 colleges and inspire you to fall in love with the college admission process. She believes you can land at your perfect destination: YOUniversity. Guest Bio Maria Furtado is the Executive Director of the non-profit organization, Colleges That Change Lives. She has worked in higher education for over 20 years, and she worked at two CTCL schools, Clark University in Worcester, Massachusetts, and Eckerd College in St Petersburg, Florida. Maria speaks all around the country to students, parents and counselors about college rankings and popular misperceptions about college admission, the strength and worth of a liberal arts education, the lifelong value of a college education – the return on investment - and offers tips for students and parents on how to manage the college search. She really enjoys helping students and families as they take on the college search process, and she believes that finding the right college should be about "fit,” not just settling or chasing the name brand. Maria also believes that it's OK, and actually preferable, to enjoy talking about colleges. She also thinks the college search should actually be fun. Get FREE College Admission Essay Help: https://www.drcynthiacolon.com/essay-mini-training Check out the Destination YOUniversity FB Group: https://www.facebook.com/groups/2489993244570408 See our website here: https://www.drcynthiacolon.com/ Schedule a call with Dr. C: https://www.drcynthiacolon.com/schedule ________________________________ #Drcynthiacolon #Collegeessaybootcamp #collegeessay #Highschool #Juniors #seniors #tipstalestruths #Tips #collegecounseling #collegeconsulting #collegeconsultingservices #collegeadmissionsconsultant #collegeadmissionsconsultingservices #bestcollegeconsultants #collegeadmissionshelp #collegeconsultant #collegeadmissionsconsulting #admissionsconsulting #college #collegeadmissions #Collegeadvice #collegeprep

This series of two podcasts leads you on a journey through the main clinical and therapeutical aspects of Cutaneous T Cell Lymphomas (CTCLs), a heterogeneous group of lymphoid neoplasms characterized by primary cutaneous localization. Albeit rare, CTCLs have peculiar clinical characteristics, requiring a multidisciplinary approach and a strict collaboration between different specialists, allowing for a timely and precise diagnosis, critical for the good outcome of these patients. Join dermatologist Prof Maarten Vermeer (Dept. of Dermatology, Leiden University Medical Center) and hematologist Dr Erik Marijt (Head of the Central Laboratory of Clinical Hematology and the Interdivisional Flowcytometry Core Facility, Leiden University Medical Center) as they exchange their views and expertise on the diagnosis and management of patients with CTCLs. In this first episode, listen to Prof Vermeer and Dr Marijt illustrating the dermatologic and hematologic approaches to the diagnosis and staging of CTCLs, including the different clinical presentation and prognosis of the most common types of CTCLs. Hosts: Prof Maarten Vermeer; Dr Erik Marijt What did you think of this podcast? Share your opinions with us in this short feedback survey. https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1 (Provide Feedback) Would you like to explore more eLearning or podcasts? Please visit the EHA Campus. https://ehacampus.ehaweb.org/ (https://ehaedu.org/Campus) Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to. Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://www.instagram.com/EHA_Hematology/) Facebook: https://e-h-a.link/facebook?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://e-h-a.link/facebook) LinkedIn: https://www.linkedin.com/company/eha/?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://www.linkedin.com/company/eha/) Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://eha.news/subscribe) 

This series of two podcasts leads you on a journey through the main clinical and therapeutical aspects of Cutaneous T Cell Lymphomas (CTCLs), a heterogeneous group of lymphoid neoplasms characterized by primary cutaneous localization. Albeit rare, CTCLs have peculiar clinical characteristics, requiring a multidisciplinary approach and a strict collaboration between different specialists, allowing for a timely and precise diagnosis, critical for the good outcome of these patients. Join dermatologist Prof Maarten Vermeer (Dept. of Dermatology, Leiden University Medical Center) and hematologist Dr Erik Marijt (Head of the Central Laboratory of Clinical Hematology and the Interdivisional Flowcytometry Core Facility, Leiden University Medical Center) as they exchange their views and expertise on the diagnosis and management of patients with CTCLs. In this second episode, listen to Prof Vermeer and Dr Marijt discussing how CTCL patients with localized and diffuse disease can be effectively treated, and how new targeted agents and allogeneic transplantation can be integrated into the management algorithm. Hosts: Prof Maarten Vermeer; Dr Erik Marijt What did you think of this podcast? Share your opinions with us in this short feedback survey. https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1 (Provide Feedback) Would you like to explore more eLearning or podcasts? Please visit the EHA Campus. https://ehacampus.ehaweb.org/ (https://ehaedu.org/Campus) Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to. Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://www.instagram.com/EHA_Hematology/) Facebook: https://e-h-a.link/facebook?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://e-h-a.link/facebook) LinkedIn: https://www.linkedin.com/company/eha/?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://www.linkedin.com/company/eha/) Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://eha.news/subscribe) 

Sen. Lisa Baker (R-Luzerne) joins Sen. Kristin Phillips-Hill to discuss legislation they are working on together that would ban outside groups from funding Pennsylvania's elections process. In 2020, the nonprofit Center for Tech and Civic Life (CTCL) pumped in more than $20 million into the Commonwealth. Further evidence shows certain counties were targeted by CTCL for funding. The senators believe that this could set a very dangerous precedent and outline why they are seeking to end the practice all together. Senate Bill 982 would restore confidence and integrity in Pennsylvania's election process.

Randy continues his deep dive into the Center for Tech and Civic Life (CTCL), the "non-partisan?" group that doled out millions in Zuckerbucks for the 2020 election.  We got the receipts thanks to the Caesar Rodney Institute for American Election Research's Chairman Joe Arlinghaus.  We discuss SofS candidate Pam Anderson's role at CTCL.  Randy believes evidence of a stolen election is right in front of our faces with more every day.  Oh, and Ceasar Rodney?  Very important to the American founding.  Listen and find out why! See omnystudio.com/listener for privacy information.

 Randy is joined by the beautiful and inspirational Michaela McLean-Wilkes.  She's the longest-reigning Miss Florida ever (2019 AND 2020!) and her Godly message for young people, especially young women, all women, is powerful.  They share their thoughts from 2022 CPAC and look into the future.  https://michaelamclean.net/. Plus more on Tina Peters, Pam Anderson, and the purchased 2020 election from Zuckerbucks running through the CTCL (https://thefederalist.com/2021/10/12/the-2020-election-wasnt-stolen-it-was-bought-by-mark-zuckerberg/). See omnystudio.com/listener for privacy information.

THE THESIS: There is enough evidence of massive vote fraud to decertify Wisconsin's 2020 election.  THE SCRIPTURE & SCRIPTURAL RESOURCES:  Proverbs 16:13-23 THE NEWS & COMMENT: The order went out from The leftist portion of The Party: tie Ukraine to US voting rights. Todd, Sharpton Lament Biden Didn't Tie Ukraine to 'Voting Rights' During SOTU  All of The Party's “best people” got to work. Jay Inslee, dictator of WA “State” pretends Ukraine = US voting rights  Pramilla PayPal on MSNBC: Democracy in America Is Under Threat, Just Like In Ukraine Also on MSNBC: Sarah Kendzior: "Trump was installed as the president of the United States in order to weaken the alliances that were preventing Putin from achieving his goals. Alliances like NATO, our relationship with our European partners...with Ukraine. But, it's not just the voting rights about which they pretend to worry . . .  And--choke, gag, puke--more from MSNBC: The View Cheers as Extremist Guest Declares Constitution Is 'Trash' Has your favorite news outlet been covering this massive US convoy, or nah?? Wisconsin Special Counsel Finds ‘Widespread Election Fraud' In 2020 Nursing Home Special Counsel Finds Mark Zuckerberg's Election Money Violated Wisconsin Bribery Laws . . . That is local news in Wisconsin, on NBC  . . . but, NO national news stories of note! WMTV: Breaking down the ‘Zuckerberg 5′ in Wisconsin election report; CTCL derides allegations The Biden Admin is illegally demanding tech companies provide info on Americans engaged in wrongthink and the NYT writes it up as if this is just a legit attempt at purging “misinformation”  See omnystudio.com/listener for privacy information.

In today's episode:The podcast is (mostly) back online, so please bear with me while I continue to make adjustments - if you're having trouble with Apple and Spotify, there are plenty of other great podcast apps (I'm using PodcastGuru)FOIA'd documents show the fake administration paid $1 billion in taxpayer funds to media organizations and influencers to spread propaganda about how the "vaccines" were safe and effectiveOther FOIA'd docs show NBC promising to give favorable coverage to a domestic terrorist Biden nominated to lead the Bureau of Land ManagementDon't worry, they have policies that prevent this stuff, so it didn't happenRussia claims, now with evidence, that the US and Ukraine were building functional bioweapons labs in Ukraine near the Russian border (but it's still a conspiracy theory for now)Mississippi elections officials have been caught 'stealing' Mark Zuckerberg's CTCL money that was supposed to be used to steal the electionSeth Keshel reveals rampant election fraud in the Texas primaries as the GOP establishment manipulated the elections causing popular America First candidates to "lose"Election fraud cannot be fixed through fraudulent elections, period.To support directly:  ko-fi.com/imyourmoderatorbtc via coinbase: 3MEh9J5sRvMfkWd4EWczrFr1iP3DBMcKk5Merch site: www.cancelcouture.com or shop.spreadshirt.com/cancel-coutureWriting at: imyourmoderator.substack.comFollow the podcast info stream: t.me/imyourmoderator or on Truth Social, Gab, or Gettr @imyourmoderatorSupport the show (https://www.ko-fi.com/imyourmoderator)

In today's episode:The podcast is (mostly) back online, so please bear with me while I continue to make adjustments - if you're having trouble with Apple and Spotify, there are plenty of other great podcast apps (I'm using PodcastGuru)FOIA'd documents show the fake administration paid $1 billion in taxpayer funds to media organizations and influencers to spread propaganda about how the "vaccines" were safe and effectiveOther FOIA'd docs show NBC promising to give favorable coverage to a domestic terrorist Biden nominated to lead the Bureau of Land ManagementDon't worry, they have policies that prevent this stuff, so it didn't happenRussia claims, now with evidence, that the US and Ukraine were building functional bioweapons labs in Ukraine near the Russian border (but it's still a conspiracy theory for now)Mississippi elections officials have been caught 'stealing' Mark Zuckerberg's CTCL money that was supposed to be used to steal the electionSeth Keshel reveals rampant election fraud in the Texas primaries as the GOP establishment manipulated the elections causing popular America First candidates to "lose"Election fraud cannot be fixed through fraudulent elections, period.To support directly:  ko-fi.com/imyourmoderatorbtc via coinbase: 3MEh9J5sRvMfkWd4EWczrFr1iP3DBMcKk5Merch site: www.cancelcouture.com or shop.spreadshirt.com/cancel-coutureWriting at: imyourmoderator.substack.comFollow the podcast info stream: t.me/imyourmoderator or on Truth Social, Gab, or Gettr @imyourmoderatorSupport the show (https://www.ko-fi.com/imyourmoderator) See acast.com/privacy for privacy and opt-out information. Become a member at https://plus.acast.com/s/be-reasonable-with-your-moderator-chris-paul.

In this episode, Steven M. Horwitz, MD; Francine Foss, MD; and Barbara Pro, MD, answer questions from an audience of healthcare professionals on topics related to the management of patients with T-cell lymphomas including:Threshold of CD30 positivity useful to inform brentuximab vedotin use in patients with CTCL and PTCLManaging relapsed mycosis fungoides after allogeneic SCTExperience with ALK inhibition in ALCL with central nervous system metastasesManaging refractory pruritus in CTCLRole of PI3K inhibitors in frontline and relapsed/refractory PTCLWhen to consider SCT in CTCL cycling through monotherapiesPresenters:Steven M. Horwitz, MDMemberMemorial Sloan Kettering Cancer CenterAttending PhysicianMemorial HospitalProfessor of MedicineWeill Cornell Medical College  New York, New YorkFrancine Foss, MDProfessor of Medical OncologyYale Cancer CenterYale University School of MedicineNew Haven, ConnecticutBarbara Pro, MDProfessor of MedicineDivision of Hematology/OncologyNorthwestern UniversityChicago, IllinoisLink to the complete program, including downloadable slidesets, an expert commentary, and on-demand webcast, and healthcare professional resource guide:https://bit.ly/3AKJE5s

HOW ZUCK BOUGHT THE 2020 ELECTIONPrevious Article: https://gorightnews.com/how-zuck-bought-the-2020-election/https://www.spreaker.com/user/peterboykin/how-zuck-bought-the-2020-electionA stunning new analysis of tax disclosures reveals how much Mark Zuckerberg funneled $350 million dollars into key swing states during the 2020 election and how that money disproportionately funded turn-out efforts in Biden-friendly districts. We reported on this last month, but new details show just how lopsided it was.First things first: Zuckerberg funneled his Zuck-bucks through a nonprofit company called the Center for Technology and Civic Life (CTCL). According to InfluenceWatch.org, CTCL is:a left-learning election reform advocacy group that pushes for Democrat voting policies. Its founders were part of the now-defunct "New Organizing Institute" which the Washington Post described as “the Democratic Party's Hogwarts for digital wizardry."Seems like an unbiased arbiter, right...

HOW ZUCK BOUGHT THE 2020 ELECTIONA vote-generating group funded mostly by Facebook's Mark Zuckerberg dumped money in eight swing states in 2020, with 90% of the funding going to boost turnout in Democrat counties in the 2020 election.Here's how the money breaks down: Zuckerberg's 'Center for Tech and Civic Life' spent $144 million to boost voter turnout in the 2020 election. Here's where it went:$130 million went to Democratic counties$14 million to Republican countiesLet me repeat: 90% of Zuck's funding went to boosting DEMOCRAT turnout. This money was spent primarily in Wisconsin, but also went to Georgia, Minnesota, Pennsylvania, Ohio, Florida, Nevada, Texas, and New York.Rep. Claudia Tenney, co-chairwoman of the House Election Integrity Caucus, said: “After reviewing their IRS Form 990, which I requested months ago, we know the group gave overwhelmingly to Democrat-leaning counties to drive up voter turnout there. This provided Democrats with a clear advantage over Republicans, and now we have the evidence to show the extent of this partisan exercise."Tenney continued: “CTCL's one-sided distribution of private dollars directly to election agencies without any accountability completely bypassed state and local governments and undermined the fairness and integrity of our elections. It should not have happened."It shouldn't be forgotten that Trump faced severe censorship from big tech during the 2020 election - from Zuckerberg's Facebook as well as Twitter and YouTube.[Source: Washington Examiner]https://www.spreaker.com/user/9922149/how-zuck-bought-the-2020-election

Senator Kristin Phillips-Hill sits down with Rep. Eric Nelson to discuss legislation that would prohibit third-party entities from contributing to the elections process in Pennsylvania. In the 2020 General Election, the Center for Tech and Civic Life (CTCL) provided more than $20 million to Pennsylvania counties. Counties were selectively asked by state officials to apply to the nonprofit for funding. CTCL was the recipient of $350 million in donations by Facebook's Mark Zuckerberg last year.

Lauren Walrath is Vice President of Public Affairs in North America, and Susan Thiele is Director of Advocacy and Brand Communications at Kyowa Kirin, a Japan-based global specialty pharmaceutical company known for its cutting-edge scientific discoveries in four therapeutic areas including neurology, nephrology, hematological cancers, and immunology. Lauren explains their approach to patient-centric discovery, "In advocacy, we're really trying to find where the gaps are and how we can best work with partners to make long-term and sustainable improvements for patients. So that can be in the form of starting new research, funding new grants, addressing disparities, working on developing new education programs. Generally, we're looking for meaningful opportunities to help patients and their families on their journey from diagnosis to treatment. We work closely with the advocates, and we bring all of that understanding back to our teams here at Kyowa Kirin so that we really can engage our cross-functional partners in doing more to help the patients we serve." Susan elaborates, "And then there is Jim and Jeffrey who have Sézary syndrome, which is a more serious form of CTCL that affects less than 5% of the patients. What we've done is we've captured their journeys in their own voice, the journey to diagnosis, their experience on treatment, and ultimately what they've learned along the way, what really keeps them motivated to not give up. And people can now hear those stories by going to POTELIGEO.com." #KyowaKirin #KKNA #DrugDevelopment #RareDiseases #Antibodies #immunology #Cancer #CTCL #Neurology #ParkinsonsDisease #NeurodegenerativeDiseases #Nephrology #HematologicalCancers #SezarySyndrome KyowaKirin.com Download the transcript here

Lauren Walrath is Vice President of Public Affairs in North America, and Susan Thiele is Director of Advocacy and Brand Communications at Kyowa Kirin, a Japan-based global specialty pharmaceutical company known for its cutting-edge scientific discoveries in four therapeutic areas including neurology, nephrology, hematological cancers, and immunology. Lauren explains their approach to patient-centric discovery, "In advocacy, we're really trying to find where the gaps are and how we can best work with partners to make long-term and sustainable improvements for patients. So that can be in the form of starting new research, funding new grants, addressing disparities, working on developing new education programs. Generally, we're looking for meaningful opportunities to help patients and their families on their journey from diagnosis to treatment. We work closely with the advocates, and we bring all of that understanding back to our teams here at Kyowa Kirin so that we really can engage our cross-functional partners in doing more to help the patients we serve." Susan elaborates, "And then there is Jim and Jeffrey who have Sézary syndrome, which is a more serious form of CTCL that affects less than 5% of the patients. What we've done is we've captured their journeys in their own voice, the journey to diagnosis, their experience on treatment, and ultimately what they've learned along the way, what really keeps them motivated to not give up. And people can now hear those stories by going to POTELIGEO.com." #KyowaKirin #KKNA #DrugDevelopment #RareDiseases #Antibodies #immunology #Cancer #CTCL #Neurology #ParkinsonsDisease #NeurodegenerativeDiseases #Nephrology #HematologicalCancers #SezarySyndrome KyowaKirin.com Listen to the podcast here

Mycosis fungoides (MF) and Sézary syndrome (SS) are rare cutaneous T-cell lymphomas (CTCL). With a current lack of accessible treatments and insufficient patient support, affected patients are faced with an array of unmet needs, which may have a significant impact on their quality of life. In this podcast discussion, Richard Cowan, an oncologist with The Christie NHS Foundation Trust, Manchester, UK, and expert on CTCL, provides insights into both MF and SS.  

We've covered Mark Zuckerberg's financing of the administration of the 2020 elections through the Center for Tech and Civic Life before, but our guest today adds a provocative analysis to the evidence that the Facebook chief deserves a thank-you card from President Biden. In a piece originally posted at the Federalist and, as we record on Thursday October 14, the cover story of the New York Post, William Doyle of the Caesar Rodney Election Research Institute asserts that “The 2020 election wasn't stolen — it was likely bought by one of the world's wealthiest and most powerful men pouring his money through legal loopholes.” William joins me to explain his thesis. The 2020 Election Wasn't Stolen, It Was Bought By Mark Zuckerberg: https://thefederalist.com/2021/10/12/the-2020-election-wasnt-stolen-it-was-bought-by-mark-zuckerberg/ Subscribe to the podcast on your platform of choice at: https://influencewatch.fireside.fm/ • Facebook: https://www.facebook.com/capitalresearchcenter • Twitter: https://twitter.com/capitalresearch • Instagram: https://www.instagram.com/capital.research.center/ • YouTube: https://bit.ly/CRCYouTube

In this week's episode, we'll review a study providing new insights on megakaryocyte diversity and function, including a unique subpopulation that may act as immune cells. Next, we'll review research that intriguingly reveals a putative role for the PD1 gene in cutaneous T-cell lymphoma. Lastly, we'll conclude with a report demonstrating a lack of cross-reaction between the antibodies that cause vaccine-induced thrombocytopenia and thrombosis, and the COVID-19 spike protein.

25 counties received a total of $2.3 million in grants from the Center for Tech and Civic Life (CTCL) that ranged from $5,000 to $856,000 with no obligations. The Center for Tech and Civic Life is a non-profit organization that provides civic information for voters as well as tools for election officials. 25 Kansas counties applied for and were awarded $2.3 million dollars in CTCL grants. As of January 31, 2021, counties reported using 92% of their grant money  on items such as election equipment, staffing, and real estate expenses. There were no obligations associated with the acceptance of the CTCL grant.  The grants were the subject of some political concerns, and under a new state law, counties will not be able to accept these type grants in the future.

The C Report for Thursday, August 26, 2021. Watch The C Report Monday through Friday at 7:30 PM CST. Visit www.TheCReport.com --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app --- Send in a voice message: https://anchor.fm/thecreport/message Support this podcast: https://anchor.fm/thecreport/support

Tiana Epps-Johnson and her co-founders had an ambitious and critical goal; to simplify and modernize U.S. elections. To reach this goal, they established The Center for Tech and Civic Life (CTCL), whose data has been accessed over 250 million times by U.S. voters through partnerships with local election committees, Google, and Facebook. On this podcast, you'll hear from Tiana, the co-founder and Executive Director of CTCL, about the organizations' humble beginnings, how its work became crucial to fight election misinformation, and how Tiana's courage for this work has been passed down through generations. Grey Interviewer: Joey Scarillo, Senior Project Manager & Podcast Producer

The C Report for Friday, May 28, 2021. In this episode: President Trump has a candid conversation with Wayne Root, and we dive into election audit updates as Arizona hits almost 1 million ballots, Pennsylvania authorizes an investigation into the Dominion voting machines after they disenfranchised conservative voters on their May 18th primary, Judge Amero orders a halt to unsealing the absentee ballots in Georgia, Dominion pushes back on forensic audits of their machines in Michigan, and Wisconsin hires three former cops to audit the vote, but they seem to be investigating the not-for-profit Mark Zuckerberg organizations The Center for Tech and Civic Life and their operative Michael Spitzer-Rubenstein of the National Vote at Home Institute, an organization that ran the Wisconsin five 2020 presidential elections and works under Zuckerberg's CTCL. --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app --- Send in a voice message: https://anchor.fm/thecreport/message Support this podcast: https://anchor.fm/thecreport/support

In this episode: When people think “political billionaire,” Facebook CEO Mark Zuckerberg is not the one who usually comes to mind. But after the 2020 elections, maybe he should. The Center for Tech and Civic Life, funded principally to the tune of a reported $350 million by Zuckerberg and his wife through entities the couple controls, provided millions of dollars in grants to counties to support their implementation of mail-in voting and other left-of-center election administration procedures. And there is strong circumstantial evidence that those grants may have favored Democratic counties over Republican counties, contributing to Joe Biden’s victories in battleground states. Joining us to discuss his analysis of these “Zuck-bucks” in Pennsylvania is Todd Shepherd, chief investigative reporter for the website Broad and Liberty, which covers Philadelphia city and Pennsylvania state-level news and politics. Read more: https://broadandliberty.com/2021/04/13/zuckerberg-funded-grants-skewed-toward-blue-counties/' Subscribe to the podcast on your platform of choice at: https://influencewatch.fireside.fm/ • Facebook: https://www.facebook.com/capitalresearchcenter • Twitter: https://twitter.com/capitalresearch • Instagram: https://www.instagram.com/capital.research.center/ • YouTube: https://bit.ly/CRCYouTube

The C Report for Tuesday, May 11, 2021. In this episode, we continue our examination of election fraud via the headlines, and the headlines tell us constitutional lawyer, Matthew Deperno fights to expand the Antrim county investigation into a full blown forensic audit. Meanwhile, an injunction is filed in Wyndham, NH to stop the biased, sabotaged audit by Verified Voting (headed by Mark Lindeman whom is opposed to the Arizona audit), and Wisconsin busts wide open with election fraud as the mayors of the Wisconsin Five are discovered to have allowed the Center for Tech and Civic Living to run their elections. The CTCL is a Zuckerberg funded organization, and that’s not to mention under law cities can only run their own elections and state legislation is the final word. More fraud uncovered at The C Report. --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app --- Send in a voice message: https://anchor.fm/theexpodcast/message Support this podcast: https://anchor.fm/theexpodcast/support

Tiana Epps-Johnson (Founder and ED of the Center for Tech and Civic Life) joins Brianna and Eric for a conversation about the beginnings of CTCL, its core mission, and how it met the challenges of the 2020 election cycle.

Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2020.05.31.126805v1?rss=1 Authors: Wang, Z., Jiang, C., Yao, H., Chen, O., Rahman, S., Gu, Y., Huh, Y., Ji, R.-R. Abstract: Opioids, such as morphine are mainstay treatments for clinical pain conditions. Itch is a common side effect of opioids, particularly as a result of epidural or intrathecal (i.t.) administration. Recent progress has advanced our understanding of itch circuits in the spinal cord. However, the mechanisms underlying opioid-induced itch are not fully understood, although an interaction between mu opioid receptor (MOR) and gastrin-releasing peptide receptor (GRPR) in spinal GRPR-expressing neurons has been implicated. In this study we investigated the cellular mechanisms of intrathecal (i.t.) opioid-induced itch by conditional deletion of MOR-encoding Oprm1 in distinct populations of interneurons and sensory neurons. We found that i.t. injection of the MOR agonists morphine or DAMGO elicited dose-dependent scratching, but this pruritus was totally abolished in mice with a specific Oprm1 deletion in Vgat+ neurons (Oprm1-Vgat). Loss of MOR in somatostatin+ interneurons and TRPV1+ sensory neurons did not affect morphine-induced itch but impaired morphine-induced antinociception. In situ hybridization revealed Oprm1 expression in 30% of inhibitory and 20% of excitatory interneurons in the spinal dorsal horn. Whole-cell recordings from spinal cord slices showed that DAMGO induced outward currents in 9 out of 19 Vgat+ interneurons examined. Morphine also inhibited action potentials in Vgat+ interneurons and suppressed evoked IPSCs in postsynaptic Vgat- excitatory neurons, suggesting a mechanism of disinhibition by MOR agonists. Notably, morphine-elicited itch was suppressed by i.t. administration of NPY and abolished by spinal ablation of GRPR+ neurons, whereas i.t. GRP-induced itch response remained intact in mice lacking Oprm1-Vgat. Additionally, chronic itch from DNFB-induced allergic contact dermatitis was decreased by Oprm1-Vgat deletion. Finally, naloxone, but not peripherally restricted naloxone methiodide, inhibited chronic itch in the DNFB model and the cutaneous T-cell lymphoma (CTCL) model, indicating a contribution of central MOR signaling to chronic itch. Our findings demonstrate that i.t. morphine elicits itch via acting on MOR on spinal inhibitory interneurons, leading to disinhibition of the spinal itch circuit. Our data also suggest that chronic itch could be effectively treated with CNS-targeted naloxone. Copy rights belong to original authors. Visit the link for more info

The Evolving Landscape in Advanced CTCL: Can Emerging Therapies Enhance Patient Management?

The Evolving Landscape in Advanced CTCL: Can Emerging Therapies Enhance Patient Management?

The Evolving Landscape in Advanced CTCL: Can Emerging Therapies Enhance Patient Management?

The Evolving Landscape in Advanced CTCL: Can Emerging Therapies Enhance Patient Management?

The Evolving Landscape in Advanced CTCL: Can Emerging Therapies Enhance Patient Management?

The Evolving Landscape in Advanced CTCL: Can Emerging Therapies Enhance Patient Management?

Dr. Robert Gniadecki speaks with JCMS Editor-in-chief, Dr. Kirk Barber, about the article Gniadecki co-authored in the Sept/Oct 2019 edition of the Journal of Cutaneous Medicine and Surgery. They discuss two progressive primary cutaneous T-cell lymphomas for which there are no curative treatments, Mycosis fungoides and Sézary syndrome. Dr Gniadecki explains why Immunotherapy seems to be a promising avenue to achieve long-term disease control in CTCL, with compelling evidence indicating that Mycosis fungoides and Sézary syndrome are immunogenic lymphomas, which can be recognized by the patient’s immune system. They also discuss how current genomic techniques, such as estimating the mutational load by whole genome sequencing and neoantigen calling, are likely to provide clinically useful information facilitating personalized immunotherapy of CTCL. Dr. Robert Gniadecki is a professor of dermatology at the University of Alberta in Edmonton, where he is the director of the division of Dermatology and leads the Multidisciplinary Cutaneous Lymphoma Clinic. Theme music by Lee Rosevere Produced by David McGuffin, Explore Podcast Productions, Ottawa

Dr. Robert Gniadecki speaks with JCMS Editor-in-chief, Dr. Kirk Barber, about the article Gniadecki co-authored in the Sept/Oct 2019 edition of the Journal of Cutaneous Medicine and Surgery. They discuss two progressive primary cutaneous T-cell lymphomas for which there are no curative treatments, Mycosis fungoides and Sézary syndrome. Dr Gniadecki explains why Immunotherapy seems to be a promising avenue to achieve long-term disease control in CTCL, with compelling evidence indicating that Mycosis fungoides and Sézary syndrome are immunogenic lymphomas, which can be recognized by the patient's immune system. They also discuss how current genomic techniques, such as estimating the mutational load by whole genome sequencing and neoantigen calling, are likely to provide clinically useful information facilitating personalized immunotherapy of CTCL. Dr. Robert Gniadecki is a professor of dermatology at the University of Alberta in Edmonton, where he is the director of the division of Dermatology and leads the Multidisciplinary Cutaneous Lymphoma Clinic.Theme music by Lee RosevereProduced by David McGuffin, Explore Podcast Productions, Ottawa

Have you had The Talk with your kids yet? No, not that talk. The one about how much you can afford to pay for college! We have advice for why this talk is important, how to discuss it, and the best time to broach the subject. We're also doing the second in our series on popular admissions myths that we're trying to dispel. Our final segment focuses on Colleges That Change Lives, the group of colleges originally identified in Loren Pope's popular book of the same name. Tune in to learn more about the criteria used to select these CTCL schools and why they might be a great fit for you.

Have you had The Talk with your kids yet? No, not that talk. The one about how much you can afford to pay for college! We have advice for why this talk is important, how to discuss it, and the best time to broach the subject. We're also doing the second in our series on popular admissions myths that we're trying to dispel. Our final segment focuses on Colleges That Change Lives, the group of colleges originally identified in Loren Pope's popular book of the same name. Tune in to learn more about the criteria used to select these CTCL schools and why they might be a great fit for you.

From the SDPA Annual Summer Dermatology Conference 2019, held June 6 – June 9, 2019 in Washington, DC. Faculty: Ginette Okoye, MD Learning Objectives: Develop an approach to evaluating patients for CTCL. Diagnose the most common types of CTCL. Manage early-stage CTCL. Determine when to refer a patient with CTCL. Posted [...]

Ken chats with Suzanne Lepley, Interim Dean of Admission at Kalamazoo College, and learns the power of positivity and sweating out stress, as well as what cookies have to do with good interview questions.Shout-outs & LinksColleges That Change Lives—"Any group that works in higher ed together has more power than any individual institution for the betterment of higher education."Jeff Rickey, former enrollment chief at Earlham College who was an early mentor to Suzanne Marty O'Connell—former executive director of CTCL and mentor to Suzanne. Rapid DescentSuzanne's walkout song: No Sleep Till Brooklyn by Beastie BoysBest thing she's read lately: Where the Crawdads Sing by Delia OwensWhat she's eager to read next: Becoming by Michelle ObamaFavorite thing to make in the kitchen: Superhero muffins (for her swimmer daughter)What she uses to take and keep notes: Shinola notebooks made in Detroit, written with the Pilot Precise V5RT. Also, for color-coding, Paper Mate Flair felt tips.Memorable bit of advice: "People first. Put people first."Bucket list: a yoga retreat in Italy (combines her three favorite things, yoga, food, and Italy)Episode sponsorMany thanks to RHB, a marketing and design consultancy serving higher education and helping great causes succeed since 1991.

Mycosis fungoides and other cutaneous T cell lymphomas (CTCL) can be a confusing and complicated topic.  We will simplify CTCL and discuss the pathogenesis, diagnosis, and treatment of mycosis fungoides. Connect with us:         •       Facebook:  https://www.facebook.com/learndermpodcast/         •       IG: https://www.instagram.com/learndermpodcast/?hl=en         •       Website (includes episode study guide!):  www.learndermpodcast.com … Continue reading "Ep7 PSQ – Mycosis Fungoides"

With are privileged to take a moment to sit down with Oberlin College President Carmen Twillie Ambar to discuss about the great history of Oberlin College, the interesting opportunities at liberal art colleges and even the issues with higher education with even the recent Varsity Blues scandal. Listen in and learn how Oberlin College integrates a "rich array of experiences" for students in academic life, internships, social and professional life and the VAST experiences and insight from President Carmen Twillie Ambar.

With are privileged to take a moment to sit down with Oberlin College President Carmen Twillie Ambar to discuss about the great history of Oberlin College, the interesting opportunities at liberal art colleges and even the issues with higher education with even the recent Varsity Blues scandal. Listen in and learn how Oberlin College integrates a "rich array of experiences" for students in academic life, internships, social and professional life and the VAST experiences and insight from President Carmen Twillie Ambar.

In this episode of Demystifying College Admissions, I’m interviewing Maria Furtado, the executive director of Colleges That Change Lives. The mission of CTCL is to help students and families better understand the college admissions process to find the best college fit possible. WHAT YOU’LL LEARN ABOUT IN THIS EPISODE: The practicality piece of getting accepted into an Ivy League Why the Ivy Leagues will not be the best for every student. Why it’s a mistake to apply to all 8 Ivy Leagues The importance of being true to yourself. Why there’s a cultural need to meet an expectation Why students need the freedom to be who they are The importance of building your back-up schools How many schools you should have on your final college list What action steps parents can take during their children’s college admissions journey The “Course catalog” exercise!    NOTABLE QUOTES: “All we can do is give our students factual information.” “Is your child amazing in a national or International pool?” “Your parental perspective doesn’t change the fact that these schools (Ivy Leagues) receive 10x the applications than they can admit” “Do you think your child will thrive here?” “Expand your horizons by one” “There’s nothing that’s going to cause a sweeping change”   “Be honest with your answers”   “Own your search” “Be braver” SHOW NOTES:  http://www.juliekimconsulting.com/episode-17-colleges-that-change-lives STRATEGY SESSION:  http://www.juliekimconsulting.com/now 

The post 083: Ursinus College [CTCL] appeared first on The Scholarship Shark.

The post 082: St. John's College [CTCL] appeared first on The Scholarship Shark.

Colleges that Change Lives – Reed CollegeEpisode 81 This is our fourth episode in the 6-part series on Colleges That Change Lives (CTCL). Our guest speaker is Milyon Trulove, Vice President and Dean of Admission and Financial Aid, at Reed College located in Portland, Ore. At 1,400 students, Reed is a small, liberal arts college. […]The post 081: Reed College [CTCL] appeared first on The Scholarship Shark.

Colleges that Change Lives – New College of FloridaEpisode 80 This is our third episode in the 6-part series on Colleges That Change Lives (CTCL). Sharon Alcock, Associate Director of New Student Recruitment, is actively engaged in recruitment efforts for the New College of Florida. New College of Florida, a public liberal arts college, offers […]The post 080: New College of Florida [CTCL] appeared first on The Scholarship Shark.

Topics: Essentials of CTCL: What You Need to Know Faculty: Alain Rook, MD From the SDPA Annual Summer Dermatology Conference 2017. Learning Objectives: 1. Learn to distinguish early CTCL from other papulosquamous disorders 2. Learn the importance of diagnosing erythrodermic CTCL and distinguishing it from other causes of erythroderma 3. [...]

Host Brian Wesolowski sits down with CDT Senior Technologist Maurice Turner, who gives a report from DEF CON’s Voting Village. Not surprisingly, hackers yet again exposed some glaring vulnerabilities in America’s voting infrastructure.  And then Brian talks to Tiana Epps-Johnson, the Founder and Executive Director of the Center for Technology and Civic Life about how her organization is working to make the internet improve the democratic process - and yes, that includes elections. More on our election security work: http://bit.ly/CDTelectsec More from CTCL: https://www.techandciviclife.org/ More on Maurice: https://twitter.com/TypeMRT More on Tiana: https://twitter.com/tianaej More on our host, Brian: bit.ly/cdtbrian Attribution: sounds used from Psykophobia, Taira Komori, BenKoning, Zabuhailo, bloomypetal, guitarguy1985, bmusic92, and offthesky of freesound.org.

Advances in the Treatment of CTCL with guest Dr. Michael Girardi June 3, 2018 Yale Cancer Center visit: http://www.yalecancercenter.org email: canceranswers@yale.edu call: 203-785-4095

Advances in the Treatment of CTCL with guest Dr. Michael Girardi June 3, 2018 Yale Cancer Center visit: http://www.yalecancercenter.org email: canceranswers@yale.edu call: 203-785-4095

Advances in the Treatment of CTCL with guest Dr. Michael Girardi June 3, 2018 Yale Cancer Center visit: http://www.yalecancercenter.org email: canceranswers@yale.edu call: 203-785-4095

In its early stages, cutaneous t-cell lymphoma (CTCL) may be mistaken for a skin condition like eczema. Many people have… The post CTCL: Skin Lymphoma, Not Skin Cancer first appeared on The Bloodline with LLS.

In its early stages, cutaneous t-cell lymphoma (CTCL) may be mistaken for a skin condition like eczema. Many people have… The post CTCL: Skin Lymphoma, Not Skin Cancer appeared first on The Bloodline with LLS.

From the SDPA 14th Annual Fall Dermatology Conference 2016, held November 3 – 6 in Las Vegas, Nevada. Topic: Treatment Updates in CTCL Faculty: David Wada, MD; Mark Hyde, MMS, PA-C Learning Objectives: 1.) Recognize the potential for diagnostic uncertainty and ensure correct diagnosis is established 2.) Know the subtypes [...]

  In this paradigm-shifting interview with Maria Furtado, the Executive Director of Colleges That Change Lives (aka CTCL), we discuss, among other things: What is a liberal arts education and why is it important? Three questions every student should ask when it comes to picking a college Three ways to reduce anxiety during the college application process: the Car Idea, how to avoid “college creep,” and how the Ice Cream Prize can make a tour better One great way to increase (not decrease) stress during the college selection process How to make the most of a college fair experience Perhaps the single most important thing for parents to consider when it comes to the college application process    

Dr. Dave Wada and Mark Hyde, MMS, PA-C, stopped by the Dermcast studios during the SDPA’s 14th Annual Fall Dermatology Conference 2016, held in Las Vegas, Nevada, to discuss Cutaneous T Cell Lymphoma (CTCL).

Join us as we speak with Ian Heydecke. Ian is living purposefully and making his crazy dream a reality. Ian is a cancer warrior/fighter who is focusing on healing and wellness. Ian has been surviving with CTCL or Cutaneous T-Cell Lymphoma for the past 4 years. He's focused on raising awareness through his experiences and love of cooking. Ian's brands include: Body By Ian, which is his personal training service. Body By Ian offers training, tips, cooking, nutrition and much more. Ian's other brand, Bros That Cook is where he throws down in the kitchen. Teaching men and women who want to cook but maybe don't know how to, Ian incorporates the two brands together to educate, inform, and live purposefully.

Cutaneous T cell lymphomas are types of non-Hodgkin lymphoma that arise when infection-fighting white blood cells in the lymphatic system – called lymphocytes – become malignant and affect the skin.Photo therapy to topical creams, the first defense is to relieve the itching.Is it eczema? Is it psoriasis? When do you suspect CTCL.Mycosis fungoides is the most common type of CTCL. A primary symptom is a rash that arises initially in areas of the skin that are not normally exposed to sunlight.Listen in as Christiane Querfeld, MD and Melanie Cole, MS discuss CTCL, it's diagnoses and treatments.

Audio podcast from the 8th Annual SDPA Fall Dermatology Conference in Grapevine, TX. This was “Working Lunch – Prognosis, Staging and Treatment of CTCL with Amit G. Pandya, MD”. This session is also available as a download on iTunes through the dermcast podcast page*. Click here to visit the page [...]

Die Rekrutierung von Zellen ist ein komplexer, in mehreren Schritten ablaufender Mechanismus, der eine zentrale Bedeutung für zahlreiche biologische Prozesse, wie z.B. Entzündung, Transplantatabstoßung, Tumormetastasierung und Stammzell¬migration hat. Die Migration von Zellen aus dem Blutstrom oder einem Reservoir in ein Zielgewebe bzw. Zielorgan und umgekehrt wird durch zahlreiche spezifische und unspezifische Reize ausgelöst und orchestriert. Dies erfolgt zu einem großen Teil durch von Chemokinen regulierte Mechanismen. Chemokine sind chemotaktische Zytokine, welche an spezifische auf der Zelloberfläche exprimierte Chemokinrezeptoren (CCR) binden. Zellen mit entsprechenden Chemokinrezeptoren wandern entlang eines Chemokingradienten zum jeweiligen Ziel, z.B. einem Entzündungsherd oder einem Zielorgan. Erstes Ziel dieser Arbeit war die Analyse der Chemokinrezeptorexpression im kutanen T-Zell Lymphom (CTCL), einem Non-Hogkin-Lymphom mit primärer kutaner Manifestation. Der Nachweis von Chemokinrezeptoren erfolgte in vitro mit der Polymerasekettenreaktion (PCR), der Durchflusszytometrie und mit Migrations-versuchen. Der Chemokinrezeptornachweis auf Hautschnitten von CTCL-Patienten erfolgte mit der Immunhistochemie. Erstmals konnte der hautassoziierte Chemokinrezeptor CCR10 im Rahmen des CTCL nachgewiesen werden. Außerdem gelang der Nachweis der Chemokinrezeptoren CCR4, CCR7 und CXCR3 in Hautschnitten und Lymphknotenbiopsien. CXCR3 wurde erstmals im Sezary Syndrom, einer fortgeschrittenen und aggressiven CTCL-Unterform, beschrieben. In der Immunhistochemie wurde die stärkste CCR10-Expression in Sezary Syndrom-Hautschnitten festgestellt. In Biopsien von befallenen Lymphknoten zeigte sich ein auffälliges CCR10-Verteilungsmuster: CCR10-positive Zellen wurden im Lymphsinus nachgewiesen, drangen aber nur vereinzelt in den Lymphknoten ein. In peripheren, nicht-kutanen Lymphomen wurde CCR10 nicht nachgewiesen und ist somit vermutlich exklusiv auf dem primär kutanen CTCL exprimiert. Es ist davon auszugehen, dass CCR10 den Epidermotropismus vor allem in aggressiveren Stadien reguliert. Die Bedeutung von CCR10 für die lymphatische Metastasierung des CTCL ist noch nicht geklärt. CCR10 könnte in der Zukunft als Faktor für die klinische Einstufung des CTCL oder als Ziel für eine gezielte Tumortherapie dienen. Die gezielte Tumortherapie ist u.a. mit Chemokinantagonisten möglich. Sie erlauben die gezielte Beeinflussung der chemokingesteuerten Rekrutierung von Leukozyten, Stammzellen oder Tumorzellen. Deshalb wurde ein membranbindender Antagonist des Chemokins CCL5, als potentielles Agens für die lokale Therapie von Tumoren oder von Transplantatabstoßungen, generiert. Das Chemokin CCL5 und seine Rezeptoren spielen in der akuten Transplantatabstoßung und in der Tumorprogression, z.B. im Mammakarzinom, eine zentrale Rolle. Der CCL5-Antagonist Met-RANTES inhibiert in Transplantatabstoßungsmodellen die Rekrutierung von Leukozyten. Der akute Entzündungsprozess und der daraus resultierende chronische Gefäßschäden werden so vermindert. Auch in einem Tumormodell ist ein Effekt auf die lokale Tumorprogression wahrscheinlich. Der in dieser Arbeit hergestellte CCL5-Antagonist Met-RANTES(Dimer)-GPI soll eine lokale Therapie ohne systemische Nebenwirkungen ermöglichen. Durch die erstmals beschriebene Bindung eines Chemokins oder Chemokinderivats an einen Glykosylinositolphosphatidyl (GPI)-Anker soll der Antagonist effektiv in die Zellmembranen von Endothelzellen inkorporiert werden, länger auf dem Endothel verbleiben und die benötigte Proteinmenge vermindern. Zunächst wurde durch die Erweiterung des signalgebenden N-Terminus von CCL5 der CCL5-Antagonist Met-RANTES generiert. Ein Aminosäureaustausch erzeugte ein dimerisierendes Molekül, welches einfacher als die zur Polymerisierung neigende Wildform zu isolieren war. Das Protein wurde mit der PCR mit einem GPI-Anker fusioniert und in Chinese Hamster Ovary (CHO)-Zellen subkloniert. Met-RANTES(Dimer)-GPI wurde erfolgreich aus den CHO-Zellen isoliert und mit der Säulenchromatographie gereinigt. In in vitro-Versuchen wurde Met-RANTES(Dimer)-GPI effektiv in die Oberfläche von humanen Endothelzellen reinkorporiert und hemmte die transendotheliale Migration von Monozyten, welche bei der Transplantat¬abstoßung und bei der Tumorprogression eine wichtige Rolle spielen. Mit Met-RANTES(Dimer)-GPI präperfundierte Transplantate zeigen möglicherweise einen geringeren vaskulären Schaden bei der akuten Transplantatabstoßungsreaktion. Im Tumormodell soll eine Hemmung der Tumorinfiltration durch Monozyten, welche eine beschleunigte Tumorprogression verursachen, erreicht werden. Im Vergleich zu nicht GPI-gebundenen CCL5-Antagonisten würde eine lokale fokussierte Therapie ermöglicht und eine eventuell geringere zu applizierende Proteinmenge bei längerer Verweildauer erzielt. Die Ergebnisse dieser Arbeit erlauben zunächst einen genaueren Einblick in die Pathogenese des CTCL. Der Chemokinrezeptor CCR7 wird vor allem von fortgeschrittenen Formen mit lymphatischer Infiltration exprimiert. CCR10 wird erstmals im Zusammenhang mit dem CTCL beschrieben und vor allem von fortgeschrittenen Unterformen exprimiert. Desweiteren wurde ein membranbindender Chemokinantagonist hergestellt. Erstmals wird die Kombination eines Chemokins oder Chemokinderivats mit einem GPI-Anker beschrieben. Der Antagonist erlaubt eine hohe lokale Applikation ohne systemische Zirkulation des Agens. Mögliche Einsatzgebiete sind die gezielte Tumortherapie oder die Behandlung der Transplantatabstoßung.